175 related articles for article (PubMed ID: 24894061)
1. Antigen delivery by lipid-enveloped PLGA microparticle vaccines mediated by in situ vesicle shedding.
Hanson MC; Bershteyn A; Crespo MP; Irvine DJ
Biomacromolecules; 2014 Jul; 15(7):2475-81. PubMed ID: 24894061
[TBL] [Abstract][Full Text] [Related]
2. Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine.
Bershteyn A; Hanson MC; Crespo MP; Moon JJ; Li AV; Suh H; Irvine DJ
J Control Release; 2012 Feb; 157(3):354-65. PubMed ID: 21820024
[TBL] [Abstract][Full Text] [Related]
3. Development of a poly (lactic-co-glycolic acid) particle vaccine to protect against house dust mite induced allergy.
Joshi VB; Adamcakova-Dodd A; Jing X; Wongrakpanich A; Gibson-Corley KN; Thorne PS; Salem AK
AAPS J; 2014 Sep; 16(5):975-85. PubMed ID: 24981892
[TBL] [Abstract][Full Text] [Related]
4. The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant.
Jain S; O'Hagan DT; Singh M
Expert Rev Vaccines; 2011 Dec; 10(12):1731-42. PubMed ID: 22085176
[TBL] [Abstract][Full Text] [Related]
5. Immunopotentiator-Loaded Polymeric Microparticles as Robust Adjuvant to Improve Vaccine Efficacy.
Zhang W; Wang L; Yang T; Liu Y; Chen X; Liu Q; Jia J; Ma G
Pharm Res; 2015 Sep; 32(9):2837-50. PubMed ID: 26017300
[TBL] [Abstract][Full Text] [Related]
6. Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency.
Kazzaz J; Singh M; Ugozzoli M; Chesko J; Soenawan E; O'Hagan DT
J Control Release; 2006 Feb; 110(3):566-73. PubMed ID: 16360956
[TBL] [Abstract][Full Text] [Related]
7. Diaminosulfide based polymer microparticles as cancer vaccine delivery systems.
Geary SM; Hu Q; Joshi VB; Bowden NB; Salem AK
J Control Release; 2015 Dec; 220(Pt B):682-90. PubMed ID: 26359124
[TBL] [Abstract][Full Text] [Related]
8. Intranasal delivery of cationic PLGA nano/microparticles-loaded FMDV DNA vaccine encoding IL-6 elicited protective immunity against FMDV challenge.
Wang G; Pan L; Zhang Y; Wang Y; Zhang Z; Lü J; Zhou P; Fang Y; Jiang S
PLoS One; 2011; 6(11):e27605. PubMed ID: 22110686
[TBL] [Abstract][Full Text] [Related]
9. PLG microparticles stabilised using enteric coating polymers as oral vaccine delivery systems.
Delgado A; Lavelle EC; Hartshorne M; Davis SS
Vaccine; 1999 Jul; 17(22):2927-38. PubMed ID: 10438065
[TBL] [Abstract][Full Text] [Related]
10. Immune responses to vaccines delivered by encapsulation into and/or adsorption onto cationic lipid-PLGA hybrid nanoparticles.
Liu L; Ma P; Wang H; Zhang C; Sun H; Wang C; Song C; Leng X; Kong D; Ma G
J Control Release; 2016 Mar; 225():230-9. PubMed ID: 26826307
[TBL] [Abstract][Full Text] [Related]
11. Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery.
Diwan M; Elamanchili P; Cao M; Samuel J
Curr Drug Deliv; 2004 Oct; 1(4):405-12. PubMed ID: 16305402
[TBL] [Abstract][Full Text] [Related]
12. Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine.
Moon JJ; Suh H; Polhemus ME; Ockenhouse CF; Yadava A; Irvine DJ
PLoS One; 2012; 7(2):e31472. PubMed ID: 22328935
[TBL] [Abstract][Full Text] [Related]
13. Induction of strong immune response against a multicomponent antigen of Mycobacterium tuberculosis in BALB/c mice using PLGA and DOTAP adjuvant.
Khademi F; Sahebkar A; Fasihi-Ramandi M; Taheri RA
APMIS; 2018 Jun; 126(6):509-514. PubMed ID: 29924445
[TBL] [Abstract][Full Text] [Related]
14. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology.
San Román B; Irache JM; Gómez S; Tsapis N; Gamazo C; Espuelas MS
Eur J Pharm Biopharm; 2008 Sep; 70(1):98-108. PubMed ID: 18501572
[TBL] [Abstract][Full Text] [Related]
15. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems.
Mohanan D; Slütter B; Henriksen-Lacey M; Jiskoot W; Bouwstra JA; Perrie Y; Kündig TM; Gander B; Johansen P
J Control Release; 2010 Nov; 147(3):342-9. PubMed ID: 20727926
[TBL] [Abstract][Full Text] [Related]
16. Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation.
Wang Q; Tan MT; Keegan BP; Barry MA; Heffernan MJ
Biomaterials; 2014 Sep; 35(29):8385-93. PubMed ID: 24986256
[TBL] [Abstract][Full Text] [Related]
17. Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype.
Demento SL; Cui W; Criscione JM; Stern E; Tulipan J; Kaech SM; Fahmy TM
Biomaterials; 2012 Jun; 33(19):4957-64. PubMed ID: 22484047
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of mucoadhesive PLGA microparticles for nasal immunization.
Pawar D; Goyal AK; Mangal S; Mishra N; Vaidya B; Tiwari S; Jain AK; Vyas SP
AAPS J; 2010 Jun; 12(2):130-7. PubMed ID: 20077052
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble
Margaroni M; Agallou M; Athanasiou E; Kammona O; Kiparissides C; Gaitanaki C; Karagouni E
Int J Nanomedicine; 2017; 12():6169-6184. PubMed ID: 28883727
[TBL] [Abstract][Full Text] [Related]
20. Antigen delivery via hydrophilic PEG-b-PAGE-b-PLGA nanoparticles boosts vaccination induced T cell immunity.
Rietscher R; Schröder M; Janke J; Czaplewska J; Gottschaldt M; Scherließ R; Hanefeld A; Schubert US; Schneider M; Knolle PA; Lehr CM
Eur J Pharm Biopharm; 2016 May; 102():20-31. PubMed ID: 26940132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
